Data from the Mars Express orbiter has been used to create a visualization of "a vast system of deep and steep valleys that stretches out for around 1190 km," on Mars called Noctis Labyrinthus, ...

Dr. Dirk Schulze-Makuch believes his research into extremophiles in the Atacama could help NASA re-assess its search for ...

Following the 1990s discovery that Mars had once been a watery oasis in the solar system’s habitable zone, NASA devised a ...

The idea of Mars being host to extraterrestrial life, either currently or long ago in the past, has beguiled scientists for ...

NASA's Viking missions, launched in the mid-1970s, aimed to answer a simple question: Does life exist on Mars? Viking 1 and ...

Dirk Schulze-Makuch is a scientist who thinks NASA's Viking landers could have inadvertently destroyed the life they were ...

SAN AN­TO­NIO — Promis­ing da­ta don’t al­ways equal a stock pop. Viking Ther­a­peu­tics pre­sent­ed what an­a­lysts thought were com­pelling da­ta on an oral … ...

Nov 4 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity ...

Getty Images Viking Therapeutics shares fell Monday after reporting the latest results from trials of its weight-loss drugs. Analysts say the treatment, which is being tested in both oral and ...

Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed phase 1 data that suggest its dual agonist of GLP-1 and GIP can hold its own in a ...

SAN AN­TO­NIO — Viking Ther­a­peu­tics’ high­ly an­tic­i­pat­ed read­out of its oral an­ti-obe­si­ty pill showed a place­bo-ad­just­ed weight loss of 6.8% af­ter four weeks ...

Viking’s results provided the latest showcase of how much Wegovy and Zepbound’s market success has heightened investor attention on preliminary findings from small studies. The data are from a Phase 1 ...